Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Stock Short Interest Report for October

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 159,295 shares, a growth of 61.6% from the September 30th total of 98,600 shares. Currently, 1.0% of the company’s shares are sold short. Based on an average daily trading volume, of 3,958,965 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

ENLV has been the subject of a number of research analyst reports. Zacks Research downgraded Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research report on Tuesday, September 22nd. Finally, Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Enlivex Therapeutics currently has an average rating of “Hold” and an average target price of $4,800.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ENLV. WINTON GROUP Ltd acquired a new position in Enlivex Therapeutics during the second quarter worth $55,000. Bank of America Corp DE boosted its position in shares of Enlivex Therapeutics by 53.2% in the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after acquiring an additional 45,303 shares during the period. Finally, Susquehanna International Group LLP boosted its holdings in Enlivex Therapeutics by 1,428.5% in the 2nd quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after purchasing an additional 147,334 shares during the period. Institutional investors and hedge funds own 1.02% of the company’s stock.

Enlivex Therapeutics Trading Up 3.5%

Shares of ENLV opened at $1.46 on Wednesday. Enlivex Therapeutics has a 52-week low of $1.40 and a 52-week high of $434.40. The firm has a 50-day moving average price of $9.67 and a 200 day moving average price of $137.31.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore balance to dysregulated immune responses. The company’s approach is intended to address conditions in which excessive or uncontrolled inflammation contributes to disease progression.

Enlivex’s lead product candidate is Allocetra-OTS, an off-the-shelf cell therapy made from apoptotic cells. The therapy is designed to reprogram the immune system toward a balanced state by helping regulate the activity of immune cells, including macrophages.